From Research Optoacoustic Novelty To Imaging Established in Routine diagnosticsbroad
FRONTIER · Horizon Europe grant · 2022-04-01–2024-03-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-ACCELERATORCHALLENGES-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01. CORDIS record →
Objective
Multispectral optoacoustic tomography (MSOT) is an innovative biomedical imaging technology that allows for molecular imaging in deep tissue. This noninvasive technology enables assessment of the concentration and distribution of a variety of clinically important molecules in the body and uniquely delivers information of e.g. oxygenation, inflammation, and fibrotic changes. MSOT has already demonstrated significant scientific and clinical value across a range of diseases and applications, making it a promising tool to diagnose diseases and monitor treatment response. Despite these early successes, the technology is not yet commercially viable on the broad clinical market and currently remains effectively confined to a research environment. FRONTIER will provide iThera Medical the means to translate an optimized MSOT system (MSOT Frontier) from a research environment to application in routine clinical imaging, thereby providing clinicians worldwide a powerful new diagnostic tool.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| ITHERA MEDICAL GMBH | DE | coordinator | €2,451,121 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.